Regulation of erythropoietin production

Journal of Physiology

Volumn 589, Issue 6, 2011, Pages 1251-1258

  Jelkmann, Wolfgang ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; ANGIOTENSIN II; ASPARAGINYL HYDROXYLASE; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRON; OXYGEN; OXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG;

ANEMIA; BLOOD VOLUME; CELL DIFFERENTIATION; CELL PROLIFERATION; ENHANCER REGION; ERYTHROCYTE LIFESPAN; ERYTHROCYTOSIS; FIBROBLAST; HEMATOCRIT; HUMAN; HYDROXYLATION; HYPOXEMIA; HYPOXIA; INHIBITION KINETICS; KIDNEY CORTEX; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; STEM CELL;

ANGIOTENSIN II; ANIMALS; ANOXIA; ERYTHROCYTES; ERYTHROPOIESIS; ERYTHROPOIETIN; FEEDBACK, PHYSIOLOGICAL; HUMANS; KIDNEY;

EID: 79952613173     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2010.195057     Document Type: Review

References (69)

1. Abbrecht PH & Littell JK (1972). Plasma erythropoietin in men and mice during acclimatization to different altitudes. J Appl Physiol 32, 54-58.
2. Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM & Barrett JC (2004). Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem 92, 491-501.
3. Beall CM, Cavalleri GL, Deng L, Elston RC, Gao Y, Knight J, Li C, Liang Y, McCormack M, Montgomery HE, Pan H, Robbins PA, Shianna KV, Tam SC, Tsering N, Veeramah KR, Wang W, Wangdui P, Weale ME, Xu Z, Yang L, Zaman MJ, Zeng C, Zhang L, Zhaxi P & Zheng Y (2010). Natural selection on EPAS1 (HIF2α) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A, 107, 11459-11464.
4. Birgegard G, Wide L & Simonsson B (1989). Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol 72, 462-466.
5. Blanchard KL, Acquaviva AM, Galson DL & Bunn HF (1992). Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 12, 5373-5385.
6. Boutin AT, Weidemann A, Fu Z, Mesropian L, Gradin K, Jamora C, Wiesener M, Eckardt KU, Koch CJ, Ellies LG, Haddad G, Haase VH, Simon MC, Poellinger L, Powell FL & Johnson RS (2008). Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell 133, 223-234.
7. Brauner CJ & Wang T (1997). The optimal oxygen equilibrium curve: A comparison between environmental hypoxia and anemia. Amer Zool 37, 101-108.
8. Brines M & Cerami A (2006). Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 70, 246-250.
9. Bruegge K, Jelkmann W & Metzen E (2007). Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-hydroxylases. Curr Med Chem 14, 1853-1862.
10. Bruick RK & McKnight SL (2001). A conserved family of prolyl- 4-hydroxylases that modify HIF. Science 294, 1337-1340.
11. Bunn HF, Gu J, Huang LE, Park JW & Zhu H (1998). Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 201, 1197-1201.
12. del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G & Landazuri MO (2003). The von Hippel Lindau/hypoxia inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem 278, 48690-48695.
13. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD & Garcia JA (2009). Regulation of hypoxia-inducible factor 2α signaling by the stress-responsive deacetylase sirtuin 1. Science 324, 1289-1293.
14. Dunn A, Lo V & Donnelly S (2007). The role of the kidney in blood volume regulation: the kidney as a regulator of the hematocrit. Am J Med Sci 334, 65-71.
15. Eckardt KU, LeHir M, Tan CC, Ratcliffe PJ, Kaissling B & Kurtz A (1992). Renal innervation plays no role in oxygen-dependent control of erythropoietin mRNA levels. Am J Physiol Renal Physiol 263, F925-F930.
16. Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ & Ratcliffe PJ (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54.
17. Fandrey J, Pagel H, Frede S, Wolff M & Jelkmann W (1994). Thyroid hormones enhance hypoxia-induced erythropoietin production in vitro. Exp Hematol 22, 272-277.
18. Fisher JW (2003). Erythropoietin: Physiology and pharmacology update. Exp Biol Med 228, 1-14.
19. Freudenthaler SM, Schreeb K, Korner T & Gleiter CH (1999). Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Investig 29, 816-823.
20. Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A, Klinkhardt U, Geiger H & Scheuermann EH (2001). Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 60, 83-86.
21. Gross AW & Lodish HF (2006). Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 281, 2024-2032.
22. Gunga HC, Röcker L, Behn C, Hildebrandt W, Koralewski E, Rich I, Schobersberger W & Kirsch K (1996). Shift working in the Chilean Andes (> 3, 600 m) and its influence on erythropoietin and the low-pressure system. J Appl Physiol 81, 846-852.
23. Haase VH (2010). Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 299, F1-F13.
24. Hochachka PW, Gunga HC & Kirsch K (1998). Our ancestral physiological phenotype: an adaptation for hypoxia tolerance and for endurance performance? Proc Natl Acad Sci U S A 95, 1915-1920.
25. Hodges VM, Rainey S, Lappin TR & Maxwell AP (2007). Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol 64, 139-158.
26. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, Lin A, Smith R, Rodgers GP, Donahue RE, Klaus SJ & Tisdale JF (2007). HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110, 2140-2147.
27. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95, 7987-7992.
28. Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, Kodama T, Nagasawa T & Yamamoto M (2003). A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1β, TNF-α, or l-NMMA. FASEB J 17, 1742-1744.
29. 2 sensing. Science 292, 464-468.
30. 2-regulated prolyl hydroxylation. Science 292, 468-472.
31. Jefferson JA, Escudero E, Hurtado ME, Pando J, Tapia R, Swenson ER, Prchal J, Schreiner GF, Schoene RB, Hurtado A & Johnson RJ (2002). Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. Lancet 359, 407-408.
32. Jelkmann W (1998). Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18, 555-559.
33. Jelkmann W (2007). Erythropoietin after a century of research: younger than ever. Eur J Haematol 78, 183-205.
34. Kambe T, Tada-Kambe J, Kuge Y, Yamaguchi-Iwai Y, Nagao M & Sasaki R (2000). Retinoic acid stimulates erythropoietin gene transcription in embryonal carcinoma cells through the direct repeat of a steroid/thyroid hormone receptor response element half-site in the hypoxia-response enhancer. Blood 96, 3265-3271.
35. Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein JA, Moores SL, Erickson-Miller CL & Haase VH (2010). Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 116, 3039-3048.
36. Kato H, Ishida J, Imagawa S, Saito T, Suzuki N, Matsuoka T, Sugaya T, Tanimoto K, Yokoo T, Ohneda O, Sugiyama F, Yagami K, Fujita T, Yamamoto M, Nangaku M & Fukamizu A (2005). Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor. FASEB J 19, 2023-2025.
37. Klausen T (1998). The feed-back regulation of erythropoietin production in healthy humans. Dan Med Bull 45, 345-353.
38. Kling PJ, Dragsten PR, Roberts RA, Dos Santos B, Brooks DJ, Hedlund BE & Taetle R (1996). Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br J Haematol 95, 241-248.
39. Kochling J, Curtin PT & Madan A (1998). Regulation of human erythropoietin gene induction by upstream flanking sequences in transgenic mice. Br J Haematol 103, 960-968.
40. Koivunen P, Hirsila M, Gunzler V, Kivirikko KI & Myllyharju J (2004). Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279, 9899-9904.
41. Koury ST, Koury MJ, Bondurant MC, Caro J & Graber SE (1989). Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 74, 645-651.
42. Krajewski J, Batmunkh C, Jelkmann W & Hellwig-Bürgel T (2007). Interleukin-1β inhibits the hypoxic inducibility of the erythropoietin enhancer by suppressing hepatocyte nuclear factor-4α. Cell Mol Life Sci 64, 989-998.
43. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A & Brines M (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305, 239-242.
44. Leon-Velarde F, Monge CC, Vidal A, Carcagno M, Criscuolo M & Bozzini CE (1991). Serum immunoreactive erythropoietin in high altitude natives with and without excessive erythrocytosis. Exp Hematol 19, 257-260.
45. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JA & Robach P (2007). Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 578, 309-314.
46. Macdougall IC & Ashenden M (2009). Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 16, 117-130.
47. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE & Schofield CJ (2002). Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J 367, 571-575.
48. Mahon PC, Hirota K & Semenza GL (2001). FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15, 2675-2686.
49. Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P & Metzen E (2004). Hypoxia-inducible factor-1 promotes its degradation by induction of HIF-α-prolyl-4-hydroxylases. Biochem J 381, 761-767.
50. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER & Ratcliffe PJ (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
51. Miller ME, Cronkite EP & Garcia JF (1982). Plasma levels of immunoreactive erythropoietin after acute blood loss in man. Br J Haematol 52, 545-549.
52. Noguchi CT, Asavaritikrai P, Teng R & Jia Y (2007). Role of erythropoietin in the brain. Crit Rev Oncol Hematol 64, 159-171.
53. 2-supply to the kidneys and the production of erythropoietin. Respir Physiol 77, 111-117.
54. Paliege A, Rosenberger C, Bondke A, Sciesielski L, Shina A, Heyman SN, Flippin LA, Arend M, Klaus SJ & Bachmann S (2010). Hypoxia-inducible factor-2α-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int 77, 312-318.
55. Paus R, Bodo E, Kromminga A & Jelkmann W (2009). Erythropoietin and the skin: a role for epidermal oxygen sensing? Bioessays 31, 344-348.
56. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM & Ratcliffe PJ (1997). Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J Biol Chem 272, 11205-11214.
57. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, Elliott S & Begley CG (2010). Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115, 4264-4272.
58. Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G & Wenger RH (2006). Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem 281, 23482-23491.
59. Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S & Yamamoto M (2002). Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 100, 2279-2288.
60. Tsuchiya T, Okada M, Ueda M & Yasukochi Y (1997). Activation of the erythropoietin promoter by a point mutation from GATA to TATA in the -30 region. J Biochem (Tokyo) 121, 193-196.
61. Viault F (1890). Sur l'augmentation considérable du nombre des globules rouges dans le sang chez les habitants des hauts plateaux de l'Amérique du Sud. C R Acad Sci Paris 111, 917-918.
62. Vlahakos DV, Marathias KP & Madias NE (2010). The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 56, 558-565.
63. von Wussow U, Klaus J & Pagel H (2005). Is the renal production of erythropoietin controlled by the brain stem? Am J Physiol Endocrinol Metab 289, E82-E86.
64. Wang F, Zhang R, Wu X & Hankinson O (2010). Roles of coactivators in hypoxic induction of the erythropoietin gene. PLoS One 5, e10002.
65. Wang GL & Semenza GL (1995). Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270, 1230-1237.
66. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M & Eckardt KU (2004). Differentiating the functional role of hypoxia-inducible factor (HIF)-1α and HIF-2α (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J 18, 1462-1464.
67. Weidemann A, Kerdiles YM, Knaup KX, Rafie CA, Boutin AT, Stockmann C, Takeda N, Scadeng M, Shih AY, Haase VH, Simon MC, Kleinfeld D & Johnson RS (2009). The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest 119, 3373-3383.
68. Winslow RM, Chapman KW, Gibson CC, Samaja M, Monge CC, Goldwasser E, Sherpa M, Blume FD & Santolaya R (1989). Different hematologic responses to hypoxia in Sherpas and Quechua Indians. J Appl Physiol 66, 1561-1569.
69. Yu F, White SB, Zhao Q & Lee FS (2001). HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 98, 9630-9635.